PortfoliosLab logo
Belite Bio Inc ADR (BLTE)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US07782B1044

IPO Date

Apr 29, 2022

Highlights

Market Cap

$1.97B

EPS (TTM)

-$1.18

EBITDA (TTM)

-$17.32M

Year Range

$40.00 - $86.53

Target Price

$85.00

Short %

0.49%

Short Ratio

1.94

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart


Loading data...

Returns By Period

Belite Bio Inc ADR (BLTE) returned -3.17% year-to-date (YTD) and 45.30% over the past 12 months.


BLTE

YTD

-3.17%

1M

4.41%

6M

-24.64%

1Y

45.30%

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

-3.77%

1M

7.44%

6M

-5.60%

1Y

8.37%

5Y*

14.12%

10Y*

10.46%

*Annualized

Monthly Returns

The table below presents the monthly returns of BLTE, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025-8.02%-1.45%15.77%-7.16%-0.62%-3.17%
2024-5.07%6.49%-17.04%5.81%20.57%-6.68%8.36%-1.66%-3.70%42.09%-5.03%-0.25%37.92%
2023-0.85%10.74%-9.67%-3.24%-43.00%-13.34%62.49%47.93%-7.28%17.77%12.16%8.75%51.77%
202242.78%105.95%7.90%-4.43%4.48%-13.35%12.73%-8.01%184.66%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

With an overall rank of 79, BLTE is among the top 21% of stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of BLTE is 7979
Overall Rank
The Sharpe Ratio Rank of BLTE is 8181
Sharpe Ratio Rank
The Sortino Ratio Rank of BLTE is 7676
Sortino Ratio Rank
The Omega Ratio Rank of BLTE is 7878
Omega Ratio Rank
The Calmar Ratio Rank of BLTE is 8686
Calmar Ratio Rank
The Martin Ratio Rank of BLTE is 7575
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Belite Bio Inc ADR (BLTE) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

Belite Bio Inc ADR Sharpe ratios as of May 11, 2025 (values are recalculated daily):

  • 1-Year: 0.87
  • All Time: 1.01

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

The chart below shows the rolling Sharpe ratio of Belite Bio Inc ADR compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time. For deeper analysis or to customize the calculation, use the Sharpe ratio tool.


Loading data...

Dividends

Dividend History


Belite Bio Inc ADR doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the Belite Bio Inc ADR. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Belite Bio Inc ADR was 74.59%, occurring on Jun 23, 2023. Recovery took 120 trading sessions.

The current Belite Bio Inc ADR drawdown is 26.97%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-74.59%Jul 6, 2022244Jun 23, 2023120Dec 13, 2023364
-36.6%Nov 15, 202441Jan 16, 2025
-32.66%Feb 15, 202443Apr 17, 202430May 30, 202473
-23.75%May 9, 20228May 18, 202215Jun 9, 202223
-19.49%Jun 27, 20223Jun 29, 20222Jul 1, 20225

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Belite Bio Inc ADR over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of Belite Bio Inc ADR, comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -4.1%.


-0.40-0.30-0.20-0.100.002022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober
-0.32
-0.31
Actual
Estimate

Valuation

The Valuation section provides an overview of how Belite Bio Inc ADR is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for BLTE relative to other companies in the Biotechnology industry. Currently, BLTE has a P/S ratio of 0.0. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for BLTE in comparison with other companies in the Biotechnology industry. Currently, BLTE has a P/B value of 13.5. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items